BioSpace News Archive

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, has achieved a groundbreaking milestone in vaccine discovery with the validation of its AI-powered vaccine discovery platform, EDENTM.

Genetic Technologies Limited is pleased to announce that a Medical Research Future Fund Genomics Health Futures Mission Grant has been awarded to a group of renowned national and international research and charity organizations.

Stealth BioTherapeutics Inc. today announced its achievement of target enrollment in the NuPOWER (SPIMD-301) study in patients with primary mitochondrial myopathy (PMM).

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the publication of new research that confirms the biological activity of simufilam.

Cingulate Inc. announced the pricing of its public offering of an aggregate of 6,925,208 shares of its common stock, Series A warrants to purchase up to 6,925,208 shares of common stock and Series B warrants to purchase up to 3,462,604 shares of common stock, at a public offering price of $0.5776 per share and accompanying warrants.

Ocuphire Pharma, Inc. announced that company management will be participating in one-on-one meetings at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York City on September 11-13, 2023.

Novartis is conducting a voluntary nationwide recall at the consumer level of one lot of its Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL in the US due to crystal formation observed in some bottles, which could potentially result in incorrect dosing.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) today announced it has submitted a request for a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to discuss the proposed drug development program for HT-KIT, a new molecular entity, for the treatment of advance systemic mastocytosis (AdvSM).

Zeta Surgical, a surgical robotics and mixed reality company, announced today that the U.S. Food and Drug Administration has cleared the Zeta Cranial Navigation System, its mixed reality surgical navigation system.

The AT-PDN study, which randomized 70 patients between treatment and sham groups, included 50 patients receiving Axon Therapy in combination with conventional medical management (CMM), and 20 patients receiving a sham Axon treatment alongside CMM.